Halozyme Q1 revenue up 42% to $377M; new $1B buyback program

HALOZYME THERAPEUTICS, INC.

2026-Q1 EPS reported $1.22 vs consensus $1.56 ▼ miss (-21.8%)

Total revenue $376.7M (+42% YoY); royalty revenue $240.7M (+43% YoY).
GAAP diluted EPS $1.22 (vs $0.93); Non-GAAP diluted EPS $1.60 (vs $1.11).
New $1B share repurchase program through 2028; at least $400M expected in 2026.
Reiterated 2026 guidance: revenue $1.71B-$1.81B, Non-GAAP EPS $7.75-$8.25.
Collaborations: GSK (multiple oncology ENHANZE targets), argenx VYVGART Hytrulo FDA-approved for all gMG serotypes.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

HALOZYME THERAPEUTICS, INC. updated its first quarter ended March 31, 2026 guidance (reaffirmed).

Period: first quarter ended March 31, 2026
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On May 11, 2026, Halozyme Therapeutics, Inc. issued a press release to report its financial results for the first quarter ended March 31, 2026.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

HALOZYME THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001159036-26-000067

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.